Gain Therapeutics Inc (GANX) Stock Price, Quote & News

Company Profile

Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas in Switzerland, Spain, the United States, and Australia. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. The company's lead drug candidate is GT-02287, which is currently in...

Industry: Biotechnology

Sector: Healthcare

Phone: 301 500 1556

Website: gaintherapeutics.com

Address:

4800 Montgomery Lane, Suite 220, Bethesda, United States

Gandalf01 Nov. 15 at 12:46 AM

$GANX no secret I'm not a fan of this one hope you all get rich good luck!!! You are doing great so far keep it up!

0 · Reply

Jwelz90 Nov. 14 at 10:41 PM

$GANX Jane Street joined the party as well. I missed that one.

0 · Reply

Jwelz90 Nov. 14 at 10:35 PM

$GANX Citadel added shares and a large amount of call options. Morgan Stanley added.

0 · Reply

PaulWalter Nov. 14 at 10:07 PM

$GANX Serene.

0 · Reply

microcapspeculator Nov. 14 at 10:02 PM

$GANX BTIG Quarterly Update Gain Therapeutics(GANX): BTIG Buy 11/14/25 3Q Update: Biomarker Data Around Year End After Interesting Clinical Hints at R&amp;D Event https://gaintherapeutics.wordpress.com/2025/11/14/gain-therapeuticsganx-btig-buy-11-14-25-3q-update-biomarker-data-around-year-end-after-interesting-clinical-hints-at-rd-event/

0 · Reply

billymike Nov. 14 at 9:39 PM

$GANX also at 2:53 EST there was dark pool print of 229k shares

0 · Reply

Apiker Nov. 14 at 9:38 PM

$GANX great end of the weekly here! Pulled away from the 50! Enjoy the weekend!!

0 · Reply

billymike Nov. 14 at 9:36 PM

$GANX going into weekend with 692,000 views

0 · Reply

whodat2025 Nov. 14 at 9:36 PM

$GANX great week guys. Tough market and we showed a lot of resilience. Excited to see the data soon. Any day, my friends. Have a great weekend everyone

0 · Reply

Dave2468999077844 Nov. 14 at 9:05 PM

$GANX awesome week in a crappy market. lookin for 4 next friday.

0 · Reply

Gain Therapeutics Reports Financial Results for Third Quarter 2025 and Provides Corporate Update

Nov 7, 2025, 4:16 AM EST - 7 days ago

Gain Therapeutics: Valuation Remains Low In Light Of Recently Reported Functional Improvement In PD Patients

Oct 30, 2025, 7:00 AM EDT - 15 days ago

Gain Therapeutics to Present at Neuroscience 2025

Oct 16, 2025, 7:00 AM EDT - 4 weeks ago

Gain Therapeutics to Attend the 2025 Maxim Growth Summit

Oct 9, 2025, 7:00 AM EDT - 5 weeks ago

Gain Therapeutics to Host Virtual KOL Event on GT-02287 for Parkinson's Disease

Oct 6, 2025, 8:15 AM EDT - 5 weeks ago

Gain Therapeutics Presents Initial Data from Phase 1b Clinical Study of GT-02287 in Parkinson's Patients at International Congress of Parkinson's Disease and Movement Disorders®

Sep 23, 2025, 7:40 AM EDT - 7 weeks ago

Gain Therapeutics to Participate at Drug Discovery Innovation Programme 2025

Sep 18, 2025, 7:41 AM EDT - 2 months ago

Gain Therapeutics Begins Its GT-02287 Phase 1b Extension Study in People with Parkinson's Disease

Sep 4, 2025, 8:00 AM EDT - 2 months ago

Gain Therapeutics Receives Australian Approval of Phase 1b Dosing Extension and Reports Positive Independent Data Monitoring Committee Recommendation

Aug 12, 2025, 7:00 AM EDT - 3 months ago

Gain Therapeutics Reports Financial Results for Second Quarter 2025 and Provides Corporate Update

Jul 24, 2025, 8:53 AM EDT - 4 months ago

Gain Therapeutics to Present at BTIG Annual Virtual Biotechnology Conference

Jul 16, 2025, 9:03 AM EDT - 4 months ago

Gain Therapeutics Announces Pricing of $7.0 Million Public Offering

Jul 15, 2025, 4:36 PM EDT - 4 months ago

Gain Therapeutics Announces Proposed Public Offering

Jun 30, 2025, 4:05 PM EDT - 4 months ago

Gain Therapeutics Announces Completion of Target Enrollment in Phase 1b Clinical Study Evaluating GT-02287 in People With Parkinson's Disease With or Without a GBA1 Mutation

Jun 10, 2025, 8:00 AM EDT - 5 months ago

Gain Therapeutics to Participate in Upcoming Investor Conferences

May 29, 2025, 8:45 AM EDT - 6 months ago

Gain Therapeutics Announces Oral Presentation at 2nd GBA1 Meeting

May 14, 2025, 7:30 AM EDT - 6 months ago

Gain Therapeutics Reports Financial Results for First Quarter 2025 and Provides Corporate Update

May 12, 2025, 7:30 AM EDT - 6 months ago

Gain Therapeutics Presents Preclinical Data at IAPRD 2025 30th World Congress on Parkinson's Disease and Related Disorders

May 1, 2025, 7:30 AM EDT - 7 months ago

Gain Therapeutics to Participate at The Citizens Life Sciences Conference

Apr 30, 2025, 7:45 AM EDT - 7 months ago

Gain Therapeutics Announces Oral Poster Presentation at IAPRD 2025 30th World Congress on Parkinson's Disease and Related Disorders

Mar 28, 2025, 8:30 AM EDT - 8 months ago

Gain Therapeutics Announces Poster Presentation at AD/PD 2025

Mar 27, 2025, 7:00 AM EDT - 8 months ago

Gain Therapeutics Reports Financial Results for the Fourth Quarter and Year End 2024 and Provides Corporate Update

Mar 14, 2025, 7:45 AM EDT - 8 months ago

Gain Therapeutics Doses First Participant in Phase 1b Clinical Trial of GT-02287 in Parkinson's Disease

Mar 6, 2025, 7:55 AM EST - 9 months ago

Gain Therapeutics Announces Oral Presentation at AD/PD 2025

Feb 6, 2025, 8:45 AM EST - 10 months ago

Gain Therapeutics CEO Gene Mack Issues Letter To Shareholders and Provides Operational Update

Feb 5, 2025, 8:30 AM EST - 10 months ago

Gain Therapeutics To Participate in Upcoming Investor Conferences

Dec 31, 2024, 12:23 PM EST - 11 months ago

Gain Therapeutics: Parkinson's Drug Candidate GT-02287 Keeps Racking Up Good Results

Dec 23, 2024, 7:30 AM EST - 11 months ago

Gain Therapeutics Initiates Phase 1b Clinical Trial of Lead Candidate GT-02287 in People with GBA1 and Idiopathic Parkinson's Disease

Dec 11, 2024, 8:30 AM EST - 1 year ago

Gain Therapeutics To Present At Biotech Showcase 2025

Oct 7, 2024, 7:00 AM EDT - 1 year ago

Gain Therapeutics Presents Preclinical GT-02287 Data at Neuroscience 2024

Oct 3, 2024, 7:00 AM EDT - 1 year ago

Gain Therapeutics to Participate at Upcoming Investor Conferences

Sep 30, 2024, 7:00 AM EDT - 1 year ago

Gain Therapeutics Presents Phase 1 GT-02287 Data at International Congress of Parkinson's Disease and Movement Disorders Demonstrating Increase in GCase Activity in Healthy Volunteers

Sep 26, 2024, 7:00 AM EDT - 1 year ago

Gain Therapeutics To Host Virtual Webinar on Results From Phase 1 Study and Design of Upcoming Phase 1b Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for Parkinson's Disease

Sep 19, 2024, 7:00 AM EDT - 1 year ago

Gain Therapeutics to Present Preclinical GT-02287 Data in Parkinson's Disease Models Including Two Late-Breakers at Neuroscience 2024

Aug 29, 2024, 7:30 AM EDT - 1 year ago

Gain Therapeutics Announces Positive Topline Results from the Phase 1 Clinical Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for Parkinson's Disease

Aug 8, 2024, 7:30 AM EDT - 1 year ago

Gain Therapeutics Reports Financial Results for Second Quarter 2024 and Provides Corporate Update

Jul 9, 2024, 7:00 AM EDT - 1 year ago

Gain Therapeutics Announces the Completion of Dosing in the Multiple Ascending Dose (MAD) of the Phase 1 Study of GT-02287, a Novel Small Molecule Therapy for Parkinson's Disease

Jul 1, 2024, 10:13 AM EDT - 1 year ago

Gain Therapeutics, Inc. (GANX) Special Call Transcript

Jun 28, 2024, 4:39 PM EDT - 1 year ago

Gain Therapeutics to Hold a Business Update Conference Call on July 1, 2024

Jun 27, 2024, 4:08 PM EDT - 1 year ago

Gain Therapeutics, Inc. Appoints Gene Mack as Interim CEO

Jun 27, 2024, 8:35 AM EDT - 1 year ago

Gain Therapeutics Presents GT-02287 Data at Federation of European Neuroscience Societies (FENS) Forum 2024 Demonstrating Improvements in Cognitive Performance in a Preclinical Model of GBA1 Parkinson's disease

Jun 25, 2024, 7:00 AM EDT - 1 year ago

Gain Therapeutics to Participate at H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference

Jun 13, 2024, 9:00 PM EDT - 1 year ago

Gain Therapeutics Announces Pricing of $11.0 Million Public Offering

May 30, 2024, 7:00 AM EDT - 1 year ago

Gain Therapeutics Announces Acceptance of Late-Breaking Abstract for Poster Presentation at Federation of European Neuroscience Societies (FENS) Forum 2024

May 29, 2024, 6:15 PM EDT - 1 year ago

Gain Therapeutics: Phase 1 Readout Awaits For Parkinson's Drug With Great Potential

May 14, 2024, 7:30 AM EDT - 1 year ago

Gain Therapeutics Reports Financial Results for First Quarter 2024 and Provides Corporate Update

Apr 24, 2024, 9:25 AM EDT - 1 year ago

Gain Therapeutics Announces Positive Results from the Single Ascending Dose (SAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for GBA1 Parkinson's Disease

Apr 8, 2024, 9:25 AM EDT - 1 year ago

Gain Therapeutics Bolsters Management Team with the Appointment of Gene Mack as Chief Financial Officer

Apr 1, 2024, 9:25 AM EDT - 1 year ago

Gain Therapeutics Strengthens Management Team and Appoints Jonas Hannestad, M.D., Ph.D. as Chief Medical Officer

Mar 26, 2024, 8:00 AM EDT - 1 year ago

Gain Therapeutics Reports Financial Results for Year End 2023 and Provides Corporate Update

Gandalf01 Nov. 15 at 12:46 AM

$GANX no secret I'm not a fan of this one hope you all get rich good luck!!! You are doing great so far keep it up!

0 · Reply

Jwelz90 Nov. 14 at 10:41 PM

$GANX Jane Street joined the party as well. I missed that one.

0 · Reply

Jwelz90 Nov. 14 at 10:35 PM

$GANX Citadel added shares and a large amount of call options. Morgan Stanley added.

0 · Reply

PaulWalter Nov. 14 at 10:07 PM

$GANX Serene.

0 · Reply

microcapspeculator Nov. 14 at 10:02 PM

0 · Reply

billymike Nov. 14 at 9:39 PM

$GANX also at 2:53 EST there was dark pool print of 229k shares

0 · Reply

Apiker Nov. 14 at 9:38 PM

$GANX great end of the weekly here! Pulled away from the 50! Enjoy the weekend!!

0 · Reply

billymike Nov. 14 at 9:36 PM

$GANX going into weekend with 692,000 views

0 · Reply

whodat2025 Nov. 14 at 9:36 PM

$GANX great week guys. Tough market and we showed a lot of resilience. Excited to see the data soon. Any day, my friends. Have a great weekend everyone

0 · Reply

Dave2468999077844 Nov. 14 at 9:05 PM

$GANX awesome week in a crappy market. lookin for 4 next friday.

0 · Reply

Love_To_Learn Nov. 14 at 8:48 PM

$ANGH $GANX ADDRESSING THEMES ASSOCIATED TO WHAT U BOTH DO FOR MARKETS

1 · Reply

Dave2468999077844 Nov. 14 at 8:25 PM

$GANX could walk in monday to double digits. only matter o time to me.

1 · Reply

billymike Nov. 14 at 8:15 PM

$GANX if im gene im trying to release data monday and go into the conference with the big swinging dick. But hey, thats me.

0 · Reply

billymike Nov. 14 at 7:57 PM

$GANX

0 · Reply

billymike Nov. 14 at 7:45 PM

$GANX it is my stated opinion that they already have some results and are waiting on others, hence the bullishness from Gene and the recent volume and accumulation. Anyone else agree with this assessment?!

1 · Reply

nevoklain_987 Nov. 14 at 7:13 PM

$GANX I understand there’s an event next week. Can someone give me a brief explanation of what this event is and what is expected to happen there??????

1 · Reply

billymike Nov. 14 at 7:11 PM

$GANX and at 2:07est a 217k dark pool print

0 · Reply

billymike Nov. 14 at 7:10 PM

$GANX VWAP is now $2.95 probably right where we close.

0 · Reply

billymike Nov. 14 at 7:06 PM

$GANX there was 185k dark pool print at 12:15 est right at vwap. They are resorting to all sorts of games to get whoever filled below $3

0 · Reply

zamped1 Nov. 14 at 7:00 PM

$GANX My hope is the company over the last week hit the ATM as plenty of shares to absorb....Gene is $MART and well schooled....Makes are leverage at the table better along with the $1.65 warrants....Make our balance sheet strong....$20 coming!!

1 · Reply

00Buckstock Nov. 14 at 6:58 PM

$GANX I’m not going into Monday with regrets, searching the couch cushions to pick up what I can before market closes, NFA.

0 · Reply

billymike Nov. 14 at 6:58 PM

$GANX i hope whoever is shorting develops Parkinsons! Ultimate Karma!

1 · Reply

Market Cap	106.91M
Revenue (ttm)	0.00
Net Income (ttm)	-20.41M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.12

Volume	1,191,700
Avg Vol	914,160
Day's Range	N/A - N/A
Shares Out	36.24M
Stochastic %K	97%
Beta	0.13
Analysts	Strong Sell
Price Target	$7.43